Cowen Research Themes 2021 has been published. Click here to learn about the year's key investment themes. >

$112 Million

Stoke Therapeutics, Inc.

Follow-on Offering

Bookrunner, November 2020

Stoke Therapeutics, Inc. is a biopharmaceutical company focused on pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. The Company develops novel antisense oligonucleotide (ASO) therapies that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to reduce non-productive mRNA and increase productive mRNA. The Company’s ASOs utilize its proprietary technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO), and are designed to increase the expression of proteins by individual genes. The Company’s lead product candidate, STK-001, is designed to treat Dravet syndrome, which is a severe and progressive genetic epilepsy.

More Like This

Jan 2021
$144 Million
DermTech logo

Follow-on Offering

Lead Left Bookrunner

View Details
Jan 2021
$225 Million

Follow-on Offering

Bookrunner

View Details
Jan 2021
$144 Million

Follow-on Offering

Bookrunner

View Details